Emery Pharma has entered into an agreement with both the University of Minnesota and Mayo Clinic to have access to their recent clinical isolates. Among these clinical isolates, there are multi-drug resistant strains of S. aureus, H. pylori, S. epidermidis, etc. for use in antimicrobial susceptibility testing (AST).
Halodine has engaged Emery Pharma for Next Generation Development of Oral and Nasal Antiseptics Active Against SARS-CoV-2 (COVID-19), see more here.
